title: Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.
abstract: BACKGROUND
  Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent capecitabine in pre-treated patients with metastatic colorectal cancer (CRC).
  
  
  METHODS
  An Institutional Review Board-approved, multi-institutional registry from 5/2008 to 8/2013 was reviewed. Patients who received DEBIRI with (X-DEBIRI) or without (DEBIRI) capecitabine were compared.
  
  
  RESULTS
  Twenty-two X-DEBIRI and 149 DEBIRI patients were compared. There was no difference in the two groups with regards to adverse events (p=0.56). During a 3- and 6-month evaluation, the disease control rate (DCR) was similar in both groups. During the 12-month evaluation, there was better DCR in the X-DEBIRI group (p=0.03). Median survival was 13 months in the DEBIRI group and 22 months in the X-DEBIRI group (log-rank test, p=0.217).
  
  
  CONCLUSIONS
  There is no additional toxicity when adding capecitabine with DEBIRI. Concurrent capecitabine may offer more durable disease control rate compared to DEBIRI-alone. Survival benefit with concurrent capecitabine was not statistically significant but there may be a trend towards improved survival.
authors.affiliation: Department of Interventional Radiology and Image Guided Therapy, University of Pittsburgh Medical Center, Pittsburgh, PA, U.S.A.
authors.forename: Olaguoke
authors.initials: O
authors.lastname: Akinwande
authors.affiliation: Department of Surgery, Division of Surgical Oncology, University of Louisville, James Graham Brown Cancer Center, Louisville, KY, U.S.A.
authors.forename: Amanda
authors.initials: A
authors.lastname: Miller
authors.affiliation: Baptist Health Hospital, Little Rock, AR, U.S.A.
authors.forename: David
authors.initials: D
authors.lastname: Hayes
authors.affiliation: Radiology and Imaging Consultants, PC, Institute of Minimally Invasive Therapy, Colorado Springs, CO, U.S.A.
authors.forename: Ryan
authors.initials: R
authors.lastname: O'Hara
authors.affiliation: Huntsville Hospital, Huntsville, AL, U.S.A.
authors.forename: Dana
authors.initials: D
authors.lastname: Tomalty
authors.affiliation: Department of Surgery, Division of Surgical Oncology, University of Louisville, James Graham Brown Cancer Center, Louisville, KY, U.S.A. robert.martin@louisville.edu.
authors.forename: Robert C G
authors.initials: RC
authors.lastname: Martin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004337:Drug Carriers; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007261:Infusions, Intra-Arterial; D000077146:Irinotecan; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008863:Microspheres; D008875:Middle Aged
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D003841:Deoxycytidine; D000069287:Capecitabine; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin
keywords: Irinotecan; capecitabine; chemoembolization; drug-eluting-beads; toxicity